Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035828 · ClinicalTrials.gov registry record · Phase 2
A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD
A Phase 2 study of Pulmonary Disease, Chronic Obstructive and Bronchitis, Chronic, sponsored by Abgenix.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT00035828 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive and Bronchitis, Chronic that has completed, run by Abgenix. The registered enrollment target is 150 participants, below the 1,042-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00035828, a Phase 2 study of Pulmonary Disease, Chronic Obstructive and Bronchitis, Chronic, has completed, sponsored by Abgenix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if ABX-IL8 will improve shortness of breath.
Conditions Studied
Interventions
- DRUG ABX-IL8
Study Locations (1)
California
- Abgenix - Fremont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2001-12 |
| Est. Completion | 2002-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035828
The ClinicalTrials.gov registry entry for NCT00035828 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,042-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (86% lower). The listed sponsor is Abgenix, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 1 intervention - of which ABX-IL8 is the first listed.
NCT00035828 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00035828 about?
NCT00035828 is a clinical study titled "A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD". To determine if ABX-IL8 will improve shortness of breath.
What is the current status of trial NCT00035828?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2001-12. Estimated completion is 2002-12.
What conditions does trial NCT00035828 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic.
What interventions are being tested in trial NCT00035828?
The interventions under investigation include: ABX-IL8 (DRUG).
Who is sponsoring clinical trial NCT00035828?
This trial is sponsored by Abgenix, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00035828 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
COMPLETED · Phase 2
-
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
COMPLETED · Phase 2
-
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
COMPLETED · Phase 2
-
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
COMPLETED · Phase 2
Explore more on PlainTrial
Pulmonary Disease, Chronic Obstructive
All registered trials for this condition
Bronchitis, Chronic
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.